Immunogenicity and Safety of Concomitant and Non-Concomit... | NCT04481191

NCT04481191

ID	Type	Description	Link
V260-074	Other Identifier	Merck Protocol Number
2020-003329-49	EudraCT Number

Status Module

Sponsor/Collaborators Module

Oversight Module

Description Module

Conditions Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Concomitant RotaTeq and IPV	Experimental	Participants will receive RotaTeq (2 mL oral dose) and IPV (0.5 mL intramuscular [IM] injection ) concomitantly at Visit 2 (15 to 21 days after Visit 1 [Day 1]), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).	Biological: RotaTeq (V260) Biological: IPV
Staggered RotaTeq and IPV	Active Comparator	Participants will receive RotaTeq (2 mL oral dose) at Visit 1 (Day 1), Visit 3 (30 to 42 days after Visit 1), and Visit 5 (30 to 42 days after Visit 3); and IPV (0.5 mL IM injection) at Visit 2 (15 to 21 days Visit 1), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).	Biological: RotaTeq (V260) Biological: IPV

Interventions

Name	Type	Description	Arm Group Labels	Other Names
RotaTeq (V260)	Biological	Live, pentavalent rotavirus vaccine administered as a 2 mL-dose oral solution	Concomitant RotaTeq and IPV Staggered RotaTeq and IPV

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Percentage of Participants Achieving Neutralizing Antibody Seroconversion to Poliovirus Types 1, 2, and 3 at 1 Month Post Dose 3 of IPV	The immunogenicity of IPV was measured using poliovirus serum neutralizing antibody assay of the National Institutes for Food and Drug Control (NIFDC), Beijing, China. Serum conversion was defined as antibody titer ≥1:8 post-vaccination in baseline seronegative participants or ≥4-fold increase in titer post-vaccination in baseline seropositive participants.	Baseline and 1 month postdose 3 of IPV (Month ~3.5)

Secondary Outcomes

Measure	Description	Time Frame
Geometric Mean Titers (GMTs) of Neutralizing Antibody to Poliovirus Types 1, 2, and 3 at 1 Month Post Dose 3 of IPV	The immune response to IPV was measured using poliovirus serum neutralizing antibody assay of the NIFDC, Beijing, China.	1 month postdose 3 of IPV (Month ~3.5)
Percentage of Participants Achieving Neutralizing Antibody Titers ≥1:8 for Poliovirus Types 1, 2, and 3 at 1 Month Post Dose 3 of IPV

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Healthy Chinese infant 48 days to 63 days of age.
Infant's legally acceptable representative provides written informed consent for the study.

Exclusion Criteria:

History of rotavirus disease, congenital gastrointestinal disorders, chronic diarrhea, failure to thrive, or abdominal surgery.
History of intussusception.
History of poliomyelitis.
Clinical evidence of active gastrointestinal illness. Note: Infants with gastroesophageal reflux disease [GERD] may participate in the study if the GERD is well controlled with or without medication.
Known or suspected impairment of immunological function, including severe combined immunodeficiency disease (SCID).
Has a fever, with an axillary temperature ≥37.5°C (or equivalent) at the time of vaccination or within 24 hours prior to vaccination. Note: The Visit 1 may be rescheduled after complete resolution of febrile illness.
Has acute disease.
Has underlying diseases such as cardiovascular, renal, liver, or blood disease.
History of known hypersensitivity to any components of rotavirus vaccine and/or IPV.
Uncontrolled epilepsy, encephalopathy, seizure, or other progressive neurological diseases.
Known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
Resides in a household with an immunocompromised person, including individuals with congenital immunodeficiency (including SCID), human immunodeficiency virus (HIV) infection, leukemia, lymphoma, multiple myeloma, generalized malignance, chronic renal failure, organ or bone marrow transplantation, or with those receiving immunosuppressive chemotherapy including long-term systemic corticosteroids.
Any condition, which in the opinion of the investigator, may interfere with the evaluation of the study objectives.
Prior administration of any rotavirus vaccines or poliovirus vaccines.
Has received inactivated or recombinant vaccines within 14 days prior to Visit 1 or live vaccines within 28 days prior to Visit 1.
Has received an investigational or non-registered product other than study vaccines or is planning to use such product during the study.
Has received immunosuppressive therapies including systemic (intramuscular, oral, or intravenous) corticosteroids. Note: Participants using non-systemic corticosteroids (e.g., topical, ophthalmic, and inhaled) are considered eligible for the study.
Has received a blood transfusion or blood products, including immunoglobulins or is planning to receive such product during the study.
Has participated in another interventional study prior to Visit 1 or expected to anytime during the study.
The infant's legally acceptable representative is unlikely to adhere to the study procedures, keep appointments or is planning to permanently relocate from the area prior to the completion of the study or to leave for an extended period when study visits would need to be scheduled.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is an investigational site or Sponsor staff member directly involved with this study.

Contacts/Locations Module

Name	Affiliation	Role
Medical Director	Merck Sharp & Dohme LLC	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Yangchun Center For Disease Prevention And Control ( Site 0001)		Yangchun	Guangdong	529600	China

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
38509699	Result	Chen S, Ying Z, Liu Y, Li Y, Yu Y, Huang M, Huang Z, Ou Z, Liao Y, Zhang Y, Liu G, Zhao W, Fu R, Shou Q, Zheng M, Liao X, Tu Y, Stek J, Hartzel J, Li C, Zhang J. A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China. Hum Vaccin Immunother. 2024 Dec 31;20(1):2324538. doi: 10.1080/21645515.2024.2324538. Epub 2024 Mar 20.

Label	URL
Merck Clinical Trials Information	View source

IPD Sharing Statement Module

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Concomitant RotaTeq and IPV	Participants received RotaTeq (2 mL oral dose) and IPV (0.5 mL intramuscular [IM] injection ) concomitantly at Visit 2 (15 to 21 days after Visit 1 [Day 1]), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
FG001	Staggered RotaTeq and IPV

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Annotation Section

No data available

No data is available for this block.

Document Section

Large Document Module

Uploaded Document Information

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot_SAP	Yes	Yes	No	Study Protocol and Statistical Analysis Plan	Jun 1, 2022

Derived Section

Miscellaneous Info Module

Submission Tracking

No data available

No data is available for this block.

Condition Browse Module

No data available

No data is available for this block.

Intervention Browse Module

Masking Info

Type of Units Analyzed

Arm/Group Information

ID	Title	Description
BG000	Concomitant RotaTeq and IPV	Participants will receive RotaTeq (2 mL oral dose) and IPV (0.5 mL intramuscular [IM] injection ) concomitantly at Visit 2 (15 to 21 days after Visit 1 [Day 1]), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
BG001	Staggered RotaTeq and IPV	Participants will receive RotaTeq (2 mL oral dose) at Visit 1 (Day 1), Visit 3 (30 to 42 days after Visit 1), and Visit 5 (30 to 42 days after Visit 3); and IPV (0.5 mL IM injection) at Visit 2 (15 to 21 days Visit 1), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
BG002	Total	Total of all reporting groups

Units	Counts
Participants	BG000200 BG001200 BG002400

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Continuous

Mean

Standard Deviation

days

Title

Denominators

Categories

Title	Measurements
	BG00053.3± 4.8 BG00153.3± 4.6 BG00253.3± 4.7

Age, Customized

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Infants and toddlers (48 to 63 days)	BG000200 BG001200 BG002

Sex: Female, Male

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG00086 BG00193 BG002

Ethnicity (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Hispanic or Latino	BG0000 BG0010 BG002

Race (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
American Indian or Alaska Native	BG0000 BG0010 BG002

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Percentage of Participants Achieving Neutralizing Antibody Seroconversion to Poliovirus Types 1, 2, and 3 at 1 Month Post Dose 3 of IPV

The immunogenicity of IPV was measured using poliovirus serum neutralizing antibody assay of the National Institutes for Food and Drug Control (NIFDC), Beijing, China. Serum conversion was defined as antibody titer ≥1:8 post-vaccination in baseline seronegative participants or ≥4-fold increase in titer post-vaccination in baseline seropositive participants.

Participants who received the 3 scheduled doses of study vaccination, adhered to guidelines for vaccine administration, provided baseline and post-vaccination blood samples within the acceptable day range, and did not have important protocol deviations are included.

Posted

Number

Percentage of Participants

Baseline and 1 month postdose 3 of IPV (Month ~3.5)

ID	Title	Description
OG000	Concomitant RotaTeq and IPV	Participants received RotaTeq (2 mL oral dose) and IPV (0.5 mL intramuscular [IM] injection ) concomitantly at Visit 2 (15 to 21 days after Visit 1 [Day 1]), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
OG001	Staggered RotaTeq and IPV	Participants received RotaTeq (2 mL oral dose) at Visit 1 (Day 1), Visit 3 (30 to 42 days after Visit 1), and Visit 5 (30 to 42 days after Visit 3); and IPV (0.5 mL IM injection) at Visit 2 (15 to 21 days Visit 1), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).

Units	Counts
Participants	OG000180 OG001187

Title

Denominators

Categories

Poliovirus Type 1

Title	Measurements
	OG00098.9 OG001100.0

Poliovirus Type 2

Title	Measurements
	OG000

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001	Difference indicates Concomitant-use Group % - Staggered-use Group %	Unstratified Miettinen & Nurminen method		< 0.001	One-sided p-value	Mean Difference (Final Values)	-1.1			2-Sided	95	-4.0	0.9					Non-Inferiority	Non-inferiority was declared when the lower bound of the 95% CI for the difference in percentages (Concomitant-use Group - Staggered-use Group) being > -10 percentage points (one-sided p-value < 0.025).

Secondary

Geometric Mean Titers (GMTs) of Neutralizing Antibody to Poliovirus Types 1, 2, and 3 at 1 Month Post Dose 3 of IPV

The immune response to IPV was measured using poliovirus serum neutralizing antibody assay of the NIFDC, Beijing, China.

Posted

Geometric Mean

95% Confidence Interval

Titers

1 month postdose 3 of IPV (Month ~3.5)

ID	Title	Description
OG000	Concomitant RotaTeq and IPV	Participants received RotaTeq (2 mL oral dose) and IPV (0.5 mL intramuscular [IM] injection ) concomitantly at Visit 2 (15 to 21 days after Visit 1 [Day 1]), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
OG001	Staggered RotaTeq and IPV	Participants received RotaTeq (2 mL oral dose) at Visit 1 (Day 1), Visit 3 (30 to 42 days after Visit 1), and Visit 5 (30 to 42 days after Visit 3); and IPV (0.5 mL IM injection) at Visit 2 (15 to 21 days Visit 1), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).

Secondary

Percentage of Participants Achieving Neutralizing Antibody Titers ≥1:8 for Poliovirus Types 1, 2, and 3 at 1 Month Post Dose 3 of IPV

The immune response to IPV was measured using poliovirus serum neutralizing antibody assay of the NIFDC, Beijing, China.

Posted

Number

95% Confidence Interval

Percentage of Participants

1 month post dose 3 of IPV (Month ~3.5)

ID	Title	Description
OG000	Concomitant RotaTeq and IPV	Participants received RotaTeq (2 mL oral dose) and IPV (0.5 mL intramuscular [IM] injection ) concomitantly at Visit 2 (15 to 21 days after Visit 1 [Day 1]), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
OG001	Staggered RotaTeq and IPV	Participants received RotaTeq (2 mL oral dose) at Visit 1 (Day 1), Visit 3 (30 to 42 days after Visit 1), and Visit 5 (30 to 42 days after Visit 3); and IPV (0.5 mL IM injection) at Visit 2 (15 to 21 days Visit 1), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).

Secondary

Percentage of Participants Achieving Neutralizing Antibody Titers ≥1:64 for Poliovirus Types 1, 2, and 3 at 1 Month Post Dose 3 of IPV

The immune response to IPV was measured using poliovirus serum neutralizing antibody assay of the NIFDC, Beijing, China.

Posted

Number

95% Confidence Interval

Percentage of Participants

1 month postdose 3 of IPV (Month ~3.5)

ID	Title	Description
OG000	Concomitant RotaTeq and IPV	Participants received RotaTeq (2 mL oral dose) and IPV (0.5 mL intramuscular [IM] injection ) concomitantly at Visit 2 (15 to 21 days after Visit 1 [Day 1]), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
OG001	Staggered RotaTeq and IPV	Participants received RotaTeq (2 mL oral dose) at Visit 1 (Day 1), Visit 3 (30 to 42 days after Visit 1), and Visit 5 (30 to 42 days after Visit 3); and IPV (0.5 mL IM injection) at Visit 2 (15 to 21 days Visit 1), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).

Secondary

Percentage of Participants With Solicited Injection-Site Adverse Events

Solicited injection-site adverse events (AEs) included erythema, swelling, induration, and pain at the IPV injection-site.

All participants who received ≥1 dose of study treatment are included.

Posted

Number

Percentage of Participants

Up to 7 days following each IPV vaccination

ID	Title	Description
OG000	Concomitant RotaTeq and IPV	Participants received RotaTeq (2 mL oral dose) and IPV (0.5 mL intramuscular [IM] injection ) concomitantly at Visit 2 (15 to 21 days after Visit 1 [Day 1]), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
OG001	Staggered RotaTeq and IPV	Participants received RotaTeq (2 mL oral dose) at Visit 1 (Day 1), Visit 3 (30 to 42 days after Visit 1), and Visit 5 (30 to 42 days after Visit 3); and IPV (0.5 mL IM injection) at Visit 2 (15 to 21 days Visit 1), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).

Units	Counts
Participants

Secondary

Percentage of Participants With Solicited Systemic Adverse Events

Solicited systemic AEs included diarrhea, vomiting, and elevated temperature (axillary temperature ≥37.5º C).

All participants who received ≥1 dose of study treatment and have data available are included.

Posted

Number

Percentage of Participants

Up to 7 days following each RotaTeq and/or IPV vaccination

ID	Title	Description
OG000	Concomitant RotaTeq and IPV	Participants received RotaTeq (2 mL oral dose) and IPV (0.5 mL intramuscular [IM] injection ) concomitantly at Visit 2 (15 to 21 days after Visit 1 [Day 1]), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
OG001	Staggered RotaTeq and IPV	Participants received RotaTeq (2 mL oral dose) at Visit 1 (Day 1), Visit 3 (30 to 42 days after Visit 1), and Visit 5 (30 to 42 days after Visit 3); and IPV (0.5 mL IM injection) at Visit 2 (15 to 21 days Visit 1), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).

Units	Counts
Participants

Secondary

Percentage of Participants With Serious Adverse Events (SAEs)

The percentage of participants with SAEs is presented. An SAE is an AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or another important medical event.

All participants who received ≥1 dose of study treatment are included.

Posted

Number

Percentage of Participants

Up to approximately 3.5 months

ID	Title	Description
OG000	Concomitant RotaTeq and IPV	Participants received RotaTeq (2 mL oral dose) and IPV (0.5 mL intramuscular [IM] injection ) concomitantly at Visit 2 (15 to 21 days after Visit 1 [Day 1]), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
OG001	Staggered RotaTeq and IPV	Participants received RotaTeq (2 mL oral dose) at Visit 1 (Day 1), Visit 3 (30 to 42 days after Visit 1), and Visit 5 (30 to 42 days after Visit 3); and IPV (0.5 mL IM injection) at Visit 2 (15 to 21 days Visit 1), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).

Units	Counts

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Concomitant RotaTeq and IPV	Participants will receive RotaTeq (2 mL oral dose) and IPV (0.5 mL intramuscular [IM] injection ) concomitantly at Visit 2 (15 to 21 days after Visit 1 [Day 1]), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).	0	189	7	189	123	189
EG001	Staggered RotaTeq and IPV	Participants will receive RotaTeq (2 mL oral dose) at Visit 1 (Day 1), Visit 3 (30 to 42 days after Visit 1), and Visit 5 (30 to 42 days after Visit 3); and IPV (0.5 mL IM injection) at Visit 2 (15 to 21 days Visit 1), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).	0	200	11	200	143	200

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Enteritis	Gastrointestinal disorders	MedDRA 25.0	Systematic Assessment	EG0000 events0 affected189 at risk EG0011 events1 affected200 at risk
Bronchitis	Infections and infestations	MedDRA 25.0	Systematic Assessment	EG0003 events3 affected189 at risk EG0010 events0 affected200 at risk
Epididymitis	Infections and infestations	MedDRA 25.0	Systematic Assessment	EG0000 events0 affected189 at risk EG0011 events1 affected200 at risk
Gastrointestinal viral infection	Infections and infestations	MedDRA 25.0	Systematic Assessment	EG0000 events0 affected189 at risk EG0011 events1 affected200 at risk
Influenza	Infections and infestations	MedDRA 25.0	Systematic Assessment	EG0000 events0 affected189 at risk EG0011 events1 affected200 at risk
Pneumonia	Infections and infestations	MedDRA 25.0	Systematic Assessment	EG0003 events3 affected189 at risk EG0016 events6 affected200 at risk
Septic shock	Infections and infestations	MedDRA 25.0	Systematic Assessment	EG0000 events0 affected189 at risk EG0011 events1 affected200 at risk
Upper respiratory tract infection	Infections and infestations	MedDRA 25.0	Systematic Assessment	EG0000 events0 affected189 at risk EG0011 events1 affected200 at risk
Motor developmental delay	Nervous system disorders	MedDRA 25.0	Systematic Assessment	EG0001 events1 affected189 at risk EG0010 events0 affected200 at risk
Pneumonia aspiration	Infections and infestations	MedDRA 25.0	Systematic Assessment	EG0000 events0 affected189 at risk EG0011 events1 affected200 at risk
Laryngeal obstruction	Respiratory, thoracic and mediastinal disorders	MedDRA 25.0	Systematic Assessment	EG0000 events0 affected189 at risk EG0011 events1 affected200 at risk

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Diarrhoea	Gastrointestinal disorders	MedDRA 25.0	Systematic Assessment	EG00043 events33 affected189 at risk EG00177 events50 affected200 at risk
Dyspepsia	Gastrointestinal disorders	MedDRA 25.0	Systematic Assessment	EG00013 events10 affected189 at risk EG00114 events13 affected200 at risk
Vomiting	Gastrointestinal disorders	MedDRA 25.0	Systematic Assessment	EG00023 events20 affected189 at risk EG00166 events39 affected200 at risk
Injection site erythema	General disorders	MedDRA 25.0	Systematic Assessment	EG00062 events45 affected189 at risk EG00145 events41 affected200 at risk
Injection site pain	General disorders	MedDRA 25.0	Systematic Assessment	EG00014 events12 affected189 at risk EG0017 events7 affected200 at risk
Pyrexia	General disorders	MedDRA 25.0	Systematic Assessment	EG00033 events30 affected189 at risk EG00148 events37 affected200 at risk
Bronchitis	Infections and infestations	MedDRA 25.0	Systematic Assessment	EG0009 events8 affected189 at risk EG00114 events13 affected200 at risk
Upper respiratory tract infection	Infections and infestations	MedDRA 25.0	Systematic Assessment	EG00040 events31 affected189 at risk EG00141 events36 affected200 at risk
Cough	Respiratory, thoracic and mediastinal disorders	MedDRA 25.0	Systematic Assessment	EG00026 events19 affected189 at risk EG00116 events14 affected200 at risk
Rhinorrhoea	Respiratory, thoracic and mediastinal disorders	MedDRA 25.0	Systematic Assessment	EG00018 events17 affected189 at risk EG00120 events18 affected200 at risk
Eczema	Skin and subcutaneous tissue disorders	MedDRA 25.0	Systematic Assessment	EG00014 events14 affected189 at risk EG00118 events12 affected200 at risk
Nasopharyngitis	Infections and infestations	MedDRA 25.0	Systematic Assessment	EG00014 events14 affected189 at risk EG00116 events14 affected200 at risk

Protocol Amendment 3 was issued after study completion. The purpose of the amendment was to update the Sponsor entity name and address.

Certain Agreements

ID	Term
C492535	RotaTeq
D022243	Rotavirus Vaccines

ID	Term
D014765	Viral Vaccines
D014612	Vaccines
D001688	Biological Products
D045424	Complex Mixtures